T cell immunoglobulin and mucin domain-containing protein 3 (TIM3), a member of the TIM
family, was originally identified as a receptor expressed on interferon-γ-producing CD4+ and …

The blockade of immune checkpoint receptors has made great strides in the treatment of
major cancers, including melanoma, Hodgkin's lymphoma, renal, and lung cancer. However …

Non-small cell lung cancer (NSCLC) is characterized by molecular heterogeneity with
diverse immune cell infiltration patterns, which has been linked to therapy sensitivity and …

The two T cell inhibitory receptors PD-1 and TIM-3 are co-expressed during exhausted T cell
differentiation, and recent evidence suggests that their crosstalk regulates T cell exhaustion …

Beginning in the first trimester, fetally derived extravillous trophoblasts (EVTs) invade the
uterus and remodel its spiral arteries, transforming them into large, dilated blood vessels …

Patients with malignant tumor treated with immunotherapy have received significant clinical
benefits over the years. Immune checkpoint blocking agents, such as anti-cytotoxic T …

Immune checkpoint blockade has shown unprecedented and durable clinical response in a
wide range of cancers. T cell immunoglobulin and mucin domain 3 (TIM3) is an inhibitory …

Hanahan and Weinberg have proposed 10 organizing principles that enable growth and
metastatic dissemination of cancer cells. These distinctive and complementary capabilities …

Acute myeloid leukemia (AML) is a heterogeneous disease characterized by the expansion
of immature myeloid cells in the bone marrow (BM) and peripheral blood (PB) resulting in …

Despite the impressive results of autologous CAR-T cell therapy in refractory B
lymphoproliferative diseases, CAR-NK immunotherapy emerges as a safer, faster, and cost …